Immunotherapy of Malignant Melanomas

  • W. G. Dippold
  • K.-H. Meyer zum Büschenfelde
Conference paper


A large number of antigens on human melanoma cells have been identified by means of monoclonal antibody technology [18, 21]. The availability of monoclonal antibodies has rapidly led to clinical investigations. Experience with monoclonal antibodies in the treatment of patients with melanoma is limited [4, 9, 10, 12, 13, 17, 19] because only small groups of patients have been treated so far. According to these studies, treatment with ganglioside antibodies appears most promising.


Human Melanoma Cell Melanoma Antigen Antigenic Phenotype Natural Killer Effector Cell Cutaneous Metastatic Melanoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC (1982) Identification of a human neuroectodermal tumor antigen (OFA-12) as ganglioside GD2. Proc Natl Acad Sci USA 79: 7629–7633PubMedCrossRefGoogle Scholar
  2. 2.
    Cheresh DA, Harper JR, Schulz G, Reisfeld RA (1984) Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA 81: 5767–5771PubMedCrossRefGoogle Scholar
  3. 3.
    Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA (1985) Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Proc Natl Acad Sci USA 82: 5155–5159PubMedCrossRefGoogle Scholar
  4. 4.
    Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 1430–1440PubMedGoogle Scholar
  5. 5.
    Dippold W, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ (1980) Cell surface antigens of human malignant melanoma: definition of six antigenic systems with monoclonal antibodies. Proc Natl Acad Sci USA 77: 6114–6118PubMedCrossRefGoogle Scholar
  6. 6.
    Dippold WG, Knuth A, Meyer zum Büschenfelde KH (1984) Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44: 806–810PubMedGoogle Scholar
  7. 7.
    Dippold WG, Knuth A, Meyer zum Büschenfelde KH (1984) Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells. Behring Inst Mitt 74: 14–18PubMedGoogle Scholar
  8. 8.
    Dippold W, Dienes HP, Knuth A, Meyer zum Büschenfelde KH (1985) Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues. Cancer Res 45: 3699–3705PubMedGoogle Scholar
  9. 9.
    Dippold WG, Knuth A, Meyer zum Büschenfelde KH (1985) Inflammatory tumor response to monoclonal antibody infusion. Eur J Cancer Clin Oncol 21: 907–912PubMedCrossRefGoogle Scholar
  10. 10.
    Goodman GE, Beaumier P, Fernyhough B, Hellström I, Hellström KE (1985) Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 3: 340–352PubMedGoogle Scholar
  11. 11.
    Hersey P, Schibeci SD, Townsend P, Burns C, Cheresh DA (1986) Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3. Cancer Res 46: 6083–6090PubMedGoogle Scholar
  12. 12.
    Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Me- lamed M, Oettgen HF, Old LJ (1985) Mouse monoclonal antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242–1246Google Scholar
  13. 13.
    Irie RF, Morton DL (1986) Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83: 8694–8698PubMedCrossRefGoogle Scholar
  14. 14.
    Irie RF, Sze LL, Saxton RE (1982) Human antibody to OFA-1, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines. Proc Natl Acad Sci USA 79: 5666–5670PubMedCrossRefGoogle Scholar
  15. 15.
    Knuth A, Dippold W, Meyer zum Büschenfelde KH (1984) Target level blocking of T-cell cytotoxicity for human malignant melanoma by monoclonal antibodies. Cell Immunol 83: 398–403PubMedCrossRefGoogle Scholar
  16. 16.
    Knuth A, Dippold WG, Meyer zum Büschenfelde KH (1985) Disialoganglioside GD3-specific monoclonal antibody in ADCC for human malignant melanoma. In: Gagnara J, Klaus SN, Paul E, Schartl M (eds) Biological, molecular and clinical aspects of pigmentation. University of Tokyo Press, Tokyo, pp 421–424Google Scholar
  17. 17.
    Larson SM, Carrasquillo JA, Krohn KA, Brown JP, McGruffin RW, Ferens JM, Graham MM, Hill LD, Beaumier PL, Hellström KE (1983) Localization of 131I-labeled p97-speciflc Fab fragments in human melanoma as a basis for radiotherapy. J Clin Inves 72: 2101–2114CrossRefGoogle Scholar
  18. 18.
    Lloyd KO (1983) Human tumor antigens: Detection and characterization with mouse mono-clonal antibodies. In: Herberman RB (ed) Basic and clinical tumor immunology. Martinus Nijhoff, The Hague, pp 160–214Google Scholar
  19. 19.
    Oldham RK, Foon KA, Morgan AC, Woodhouse CS, Schroff RW, Abrahams PG, Fer M, Schoenberger CS, Farrell M, Kimball E (1984) Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 2: 1235–1244Google Scholar
  20. 20.
    Real FX, Houghton A, Albino AP, Cordon-Cardo C, Melamed M, Oettgen HF, Old LJ (1985) Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression incultured cells and tissues. Cancer Res 45: 4401–4411PubMedGoogle Scholar
  21. 21.
    Reisfeld RA, Ferrone S (eds) (1982) Melanoma antigens and antibodies. Plenum, New YorkGoogle Scholar
  22. 22.
    Reynolds CW, Ortaldo JR (1987) Natural killer activity: the definition of a function rather than a cell type. Immunol Today 8: 172–174CrossRefGoogle Scholar
  23. 23.
    Vogel CW, Welt SW, Carswell EA, Old LJ, Müller-Eberhard HJ (1983) A murine IgG3 monoclonal antibody to a melanoma antigen that activates complement in vitro and in vivo. Immunobiology 164: 309Google Scholar
  24. 24.
    Watanabe T, Pukel C, Takeyama H, Lloyd KO, Shiku H, Li LTC, Travassos LR, Oettgen HF, Old LJ (1982) Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med 155: 1884–1889CrossRefGoogle Scholar
  25. 25.
    Welte K, Miller G, Chapman PB, Yuasa H, Natoli E, Kunicka JE, Cordon-Cardo C, Buhrer C, Old LJ, Houghton AN (1987) Stimulation of T-lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol 139: 1763–1771PubMedGoogle Scholar
  26. 26.
    Houghton A, Vadhans S et al. (1986) Clinical study of a mouse monoclonal antibody directed against GD3 ganglioside in patients with melanoma. Proc ASCO 906Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • W. G. Dippold
    • 1
  • K.-H. Meyer zum Büschenfelde
    • 1
  1. 1.Medical ClinicUniversity of MainzMainzGermany

Personalised recommendations